NO830340L - Isolering av protein og peptid fra urin - Google Patents
Isolering av protein og peptid fra urinInfo
- Publication number
- NO830340L NO830340L NO830340A NO830340A NO830340L NO 830340 L NO830340 L NO 830340L NO 830340 A NO830340 A NO 830340A NO 830340 A NO830340 A NO 830340A NO 830340 L NO830340 L NO 830340L
- Authority
- NO
- Norway
- Prior art keywords
- approx
- fraction
- adsorbent
- urine
- glycoprotein
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 31
- 108090000623 proteins and genes Proteins 0.000 title claims description 31
- 210000002700 urine Anatomy 0.000 title claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 18
- 238000002955 isolation Methods 0.000 title 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000003463 adsorbent Substances 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 3
- 235000019792 magnesium silicate Nutrition 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 11
- 108090000288 Glycoproteins Proteins 0.000 claims 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000004816 paper chromatography Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- CZTQZXZIADLWOZ-UHFFFAOYSA-O 8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C1SC2C(NC(=O)CC=3SC=CC=3)C(=O)N2C(C(=O)O)=C1C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-UHFFFAOYSA-O 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- GSJMPHIKYICTQX-UHFFFAOYSA-N magnesium;oxosilicon Chemical compound [Mg].[Si]=O GSJMPHIKYICTQX-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- SVVHVLRBGYHZKC-UHFFFAOYSA-N propane-1,2,3-triol;propan-2-one;hydrate Chemical compound O.CC(C)=O.OCC(O)CO SVVHVLRBGYHZKC-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/834—Urine; urinary system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/269,995 US4359415A (en) | 1981-06-03 | 1981-06-03 | Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO830340L true NO830340L (no) | 1983-02-01 |
Family
ID=23029451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO830340A NO830340L (no) | 1981-06-03 | 1983-02-01 | Isolering av protein og peptid fra urin |
Country Status (9)
Country | Link |
---|---|
US (1) | US4359415A (fr) |
EP (1) | EP0080502B1 (fr) |
JP (1) | JPS58991A (fr) |
BE (1) | BE893393A (fr) |
DE (1) | DE3268774D1 (fr) |
DK (1) | DK41783D0 (fr) |
ES (1) | ES8304069A1 (fr) |
NO (1) | NO830340L (fr) |
WO (1) | WO1982004261A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58134029A (ja) * | 1982-02-02 | 1983-08-10 | Nippon Chem Res Kk | 胃酸分泌抑制成分の分別採取法 |
JPS59137417A (ja) * | 1983-01-28 | 1984-08-07 | Morinaga Milk Ind Co Ltd | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
US6686455B1 (en) | 1984-07-05 | 2004-02-03 | Genentech, Inc. | Tumor necrosis factor |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5298604A (en) * | 1992-07-27 | 1994-03-29 | Sloane Nathan H | Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes |
IT1257184B (it) * | 1992-12-22 | 1996-01-10 | Applied Research Systems | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
US5562812A (en) * | 1995-04-03 | 1996-10-08 | The Penn State Research Foundation | Free flow electrophoresis device for biomolecule purification and separation in zero and one G |
CN100351267C (zh) * | 2000-05-10 | 2007-11-28 | 南京大学 | 人尿抗瘤抗菌肽及其制备和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3711377A (en) * | 1970-10-22 | 1973-01-16 | Barbara Sloane | Method of production of urokinase |
-
1981
- 1981-06-03 US US06/269,995 patent/US4359415A/en not_active Expired - Fee Related
-
1982
- 1982-05-26 DE DE8282902131T patent/DE3268774D1/de not_active Expired
- 1982-05-26 WO PCT/US1982/000716 patent/WO1982004261A1/fr active IP Right Grant
- 1982-05-26 EP EP82902131A patent/EP0080502B1/fr not_active Expired
- 1982-05-31 JP JP57092945A patent/JPS58991A/ja active Pending
- 1982-06-02 ES ES512779A patent/ES8304069A1/es not_active Expired
- 1982-06-02 BE BE0/208250A patent/BE893393A/fr not_active IP Right Cessation
-
1983
- 1983-02-01 NO NO830340A patent/NO830340L/no unknown
- 1983-02-02 DK DK0417/83A patent/DK41783D0/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK41783A (da) | 1983-02-02 |
EP0080502A1 (fr) | 1983-06-08 |
DK41783D0 (da) | 1983-02-02 |
EP0080502A4 (fr) | 1983-08-17 |
EP0080502B1 (fr) | 1986-01-29 |
BE893393A (fr) | 1982-10-01 |
DE3268774D1 (en) | 1986-03-13 |
JPS58991A (ja) | 1983-01-06 |
ES512779A0 (es) | 1983-02-16 |
WO1982004261A1 (fr) | 1982-12-09 |
ES8304069A1 (es) | 1983-02-16 |
US4359415A (en) | 1982-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kirby | A new method for the isolation of ribonucleic acids from mammalian tissues | |
TAKEBE et al. | Isolation of tobacco mesophyll cells in intact and active state | |
IE61294B1 (en) | Novel process for purification of Hepatitis A virions | |
NO830340L (no) | Isolering av protein og peptid fra urin | |
US4793996A (en) | Method of making soybean extract inhibitor | |
US4389396A (en) | Immunostimulating preparations based on ribosomal RNA's and a process for the preparation of the RNA's | |
Codington et al. | Further studies on the relationship between large glycoprotein molecules and allotransplantability in the TA3 tumor of the mouse: studies on segregating TA3-HA hybrids | |
JP2534587B2 (ja) | 微生物学的に生成されたキモシンの回収方法 | |
Hašková et al. | Part played by deoxyribonucleic acid in transplantation immunity | |
US4698301A (en) | Angiogenic factor production | |
Scholtissek et al. | Influence of p-fluorophenylalanine on the production of viral ribonucleic acid and on the utilizability of viral protein during multiplication of fowl plague virus | |
US4136168A (en) | Process for the preparation of neuraminidase from viral sources and methods of utilizing same | |
Faccioli et al. | An antiviral factor present in plants of Chenopodium amaranticolor locally infected by tobacco necrosis virus: 1. Extraction, partial purification biological and chemical properties | |
Takahashi et al. | Separation of slow reacting substance of anaphylaxis (SRS-A) from human lung into four biologically active fractions | |
Colman et al. | The role of plasmolysis in the isolation of photosynthetically active leaf mesophyll cells | |
Apte et al. | Proteolytic enzymes (bromelains) in tissue cultures of Ananas sativus (pineapple) | |
Berenblum et al. | Some Properties of" RLP"—A Factor from Sheep Spleen Capable of Inhibiting Radiation Leukemogenesis in Mice | |
TW390888B (en) | Process for enhancing the isolation of a cell-bound outer membrane protein of bordetella | |
US3660238A (en) | Extraction of asparaginase from bacterial culture | |
IKADAI et al. | Regeneration of oocyte-surface factor responsible for 1-methyladenine-induced oocyte maturation in starfish | |
Whitfeld et al. | On the chromatographic evidence for the occurrence of an infective ribonucleic acid fraction in leaves infected with tobacco mosaic virus | |
CN105147722A (zh) | 硫酸化白芨多糖的新用途及一种治疗眼表损伤的制剂 | |
Bhaskaran et al. | A factor that promotes mycelial development in Sporisorium reilianum in vitro | |
Hodes et al. | Possible use of synthetic surface-active agents for the preparation of tumour cell nuclei | |
CN108795839B (zh) | 一种石斛单细胞悬浮培养的方法 |